A detailed history of Cornercap Investment Counsel Inc transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Cornercap Investment Counsel Inc holds 20,683 shares of FATE stock, worth $47,364. This represents 0.02% of its overall portfolio holdings.

Number of Shares
20,683
Previous 43,472 52.42%
Holding current value
$47,364
Previous $142,000 49.3%
% of portfolio
0.02%
Previous 0.02%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

SELL
$3.12 - $5.57 $71,101 - $126,934
-22,789 Reduced 52.42%
20,683 $72,000
Q2 2024

Aug 08, 2024

SELL
$3.26 - $7.08 $1,108 - $2,407
-340 Reduced 0.78%
43,472 $142,000
Q1 2024

May 10, 2024

BUY
$3.54 - $8.35 $8,761 - $20,666
2,475 Added 5.99%
43,812 $321,000
Q3 2023

Nov 13, 2023

SELL
$2.02 - $5.04 $1,062 - $2,651
-526 Reduced 1.26%
41,337 $87,000
Q1 2023

May 11, 2023

BUY
$4.24 - $11.12 $177,499 - $465,516
41,863 New
41,863 $238,000

Others Institutions Holding FATE

About FATE THERAPEUTICS INC


  • Ticker FATE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,000,304
  • Market Cap $222M
  • Description
  • Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...
More about FATE
Track This Portfolio

Track Cornercap Investment Counsel Inc Portfolio

Follow Cornercap Investment Counsel Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cornercap Investment Counsel Inc, based on Form 13F filings with the SEC.

News

Stay updated on Cornercap Investment Counsel Inc with notifications on news.